← 返回前沿论文

树突状细胞疫苗策略治疗急性髓系白血病:一项系统综述

英文原题:Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review.

PubMed 2024/02/24(内容时间) Cytotherapy Q1 · IF 4.5(JCR 2025)

研究概要

我们进行了一项系统综述,支持将DC疫苗疗法作为AML的有效治疗方法。该疗法在实现缓解、增强免疫系统功能和延长总生存期方面显示出潜力。然而,需要更多研究来改进DC疫苗的制备和递送方法,并确认其长期安全性和有效性。

研究思路结论见上方概要

急性髓系白血病(AML)是一种血液系统恶性肿瘤,其特征为骨髓(BM)中未成熟血细胞增殖,导致细胞生长异常且不受调控。AML的主要治疗方式包括化疗和造血干细胞移植。然而,需要注意的是,这些治疗伴随显著的不良反应和死亡率。因此,似乎有必要寻求更有效的治疗选择,而树突状细胞(DC)疫苗治疗可以是其中一种选择。在本研究中,我们旨在探讨DC疫苗接种治疗用于AML管理的有效性。

对PubMed、Scopus、ProQuest、Web of Science和Google Scholar数据库进行了检索,以完成本系统综述。根据本研究的纳入标准对文章进行评估,并初步比较其标题或摘要。最终,获取与本综述主题相关的文章全文。采用完全缓解和部分缓解、生存期、相关免疫检测及健康相关指标来评估这种细胞免疫治疗的有效性。使用Cochrane偏倚风险评估工具独立评估研究质量。将整理的数据输入标准Excel电子表格。每个领域被评估为具有“低风险”、“高风险”或“不明确风险”的偏倚。

在确定的3986项研究中,共有11项相关试验被选入本系统评价。DC疫苗疗法能有效诱导完全缓解、部分缓解和疾病稳定。此外,还发现该治疗增强了免疫系统,表现为CD4+和CD8+T细胞、Th1细胞因子、WT1特异性T细胞以及活化NK细胞水平升高。

展开英文摘要原文

BACKGROUND AIMS: Acute myeloid leukemia (AML) is classified as a hematologic malignancy characterized by the proliferation of immature blood cells within the bone marrow (BM), resulting in an aberrant and unregulated cellular growth. The primary therapeutic modalities for AML include chemotherapy and hematopoietic stem cell transplantation. However, it is important to note that these treatments are accompanied by important adverse effects and mortality rates. Therefore, the need for more effective treatment options seems necessary, and dendritic cell (DC) vaccine therapy can be one of these options. In this study, we aim to investigate the effectiveness of DC vaccination therapy for the management of AML. METHODS: PubMed, Scopus, ProQuest, Web of Science, and Google Scholar databases were searched for this systematic review. The articles were evaluated based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, the articles related to the topic of this review were obtained in full text. The complete remission and partial remission, survival, correlative immune assays, and health-related metrics were used to evaluate this cellular immunotherapy effectiveness. The quality of the studies was assessed independently using the Cochrane risk-of-bias tools. The compiled data were input into a standard Excel spreadsheet. Each domain was evaluated as having either a "low risk," "high risk," or "unclear risk" of bias. RESULTS: Among the 3986 studies that were determined, a total of 11 correlated trials were selected for inclusion in this systematic review. DC vaccine therapy was effective in inducing complete and partial remission, and stabilization of the disease. Additionally, it was discovered that the treatment strengthened the immune system as seen by increased levels of CD4 + and CD8 + T cells, Th1 cytokines, WT1-specific T cells, and activated NK cells. CONCLUSION: We conducted a systematic review that supports the use of DC vaccine therapy as an effective treatment for AML. The therapy demonstrated potentials in achieving remission, enhancing the immune system function, and increasing overall survival. However, more studies are required to improve the methods of preparing and delivering the DC vaccine, and to confirm its long-term safety and effectiveness.

论文信息

作者
Motallebzadeh Khanmiri J、Alizadeh M、Esmaeili S、Gholami Z、Safarzadeh A、Khani-Eshratabadi M、Baghbanzadeh A、Alizadeh N
第一作者单位
Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.Iran
通讯作者单位
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.Iran
文献类型
系统综述 · 非美国政府资助研究
期刊
Cytotherapy2024 May
原文标识
PubMed 38483358 · DOI 10.1016/j.jcyt.2024.02.009